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Activation of MET by HGF plays a key role in tumor progression. Using a recently developed llama platform 
that generates human-like immunoglobulins, we selected 68 different antibodies that compete with HGF for 
binding to MET. HGF-competing antibodies recognized 4 distinct hotspots localized in different MET domains. 
We identified 1 hotspot that coincides with the known HGF β chain binding site on blades 2–3 of the SEMA 
domain β-propeller. We determined that a second and a third hotspot lie within blade 5 of the SEMA domain 
and IPT domains 2–3, both of which are thought to bind to HGF α chain. Characterization of the fourth hotspot 
revealed a region across the PSI-IPT 1 domains not previously associated with HGF binding. Individual or 
combined targeting of these hotspots effectively interrupted HGF/MET signaling in multiple cell-based bio-
chemical and biological assays. Selected antibodies directed against SEMA blades 2–3 and the PSI-IPT 1 region 
inhibited brain invasion and prolonged survival in a glioblastoma multiforme model, prevented metastatic dis-
ease following neoadjuvant therapy in a triple-negative mammary carcinoma model, and suppressed cancer cell 
dissemination to the liver in a KRAS-mutant metastatic colorectal cancer model. These results identify multiple 
regions of MET responsible for HGF-mediated tumor progression, unraveling the complexity of HGF-MET 
interaction, and provide selective molecular tools for targeting MET activity in cancer.
Introduction
Hepatocyte growth factor (HGF), also known as scatter factor, 
is a pleiotropic cytokine secreted by cells of mesenchymal origin 
that masters a characteristic biological program known as inva-
sive growth (1). This program, essential for embryo development 
and tissue regeneration, is usurped by tumor cells to survive, 
proliferate, and disseminate into the host organism. The MET 
tyrosine kinase, a high-affinity receptor for HGF, is frequently 
activated in human cancer (2). Aberrant activation of MET occurs 
by different molecular mechanisms, including receptor overex-
pression, point mutation, and autocrine stimulation (3). MET 
overexpression is the most frequent dysregulation event resulting 
from transcriptional activation triggered by microenvironmen-
tal signals including hypoxia, oxidative stress, and mitogenic sig-
naling (4–6). Anticancer agents such as angiogenesis inhibitors, 
ionizing radiations, and molecularly targeted drugs have also 
been shown to increase MET expression levels (7–9). Receptor 
upregulation results in increased sensitivity to environmental 
HGF, which is ubiquitous and accumulates in the extracellular 
matrix of tissues because of its high avidity for glycosaminogly-
cans (10). Increased MET expression can also be due to c-MET 
gene amplification, a genetic condition known to be associated 
with MET “addiction” (11). Although cancer cells harboring 
multiple copies of the c-MET gene display constitutive MET 
kinase activation, they retain sensitivity to the ligand (12), which 
selects for c-MET–amplified cancer cells in a darwinian fashion 
(13). Point mutations in the c-MET gene have been reported in 
hereditary and sporadic papillary renal carcinoma, hepatocellular 
and gastric carcinoma, and head and neck cancer (14). Interest-
ingly, mutated MET proteins require HGF stimulation in order 
to display their full oncogenic potential (15). Autocrine MET 
activation in tumors is less common, and has been reported in 
sarcomas, glioblastomas, and hematopoietic malignancies (16).
In spite of the importance of HGF/MET signaling in cancer 
biology, the mechanism by which HGF binds to and activates 
MET remains poorly understood. HGF is secreted as a precursor 
(pro-HGF) that binds to MET at high affinity but does not acti-
vate it (17). Upon proteolytic processing, pro-HGF is converted 
into an α-β heterodimeric ligand containing a high-affinity 
MET-binding site in the α chain and a low-affinity MET-bind-
ing site in the β chain (18). Cooperation between the α chain 
and the β chain is required for biological activity of HGF; while 
the α chain is sufficient for MET binding, the β chain is neces-
sary for MET activation (19). The extracellular domain (ECD) 
of MET has a modular structure encompassing a 7-bladed 
β-propeller semaphorin homology domain (SEMA), a plexin-
semaphorin-integrin homology domain (PSI), and 4 immuno-
globulin-plexin-transcription factor homology domains (IPT 
1–4). The β chain of active HGF binds to the “bottom” face of 
the β-propeller at low affinity, forming contacts with blades 2–3 
(20). In contrast, high-affinity binding of the α chain of HGF 
to MET is more complex and less understood. Indirect experi-
mental evidence suggests that it may interact with blade 5 of 
the SEMA β-propeller on one hand (21) and with the IPT region 
on the other (22). It is not clear whether these interactions can 
occur concomitantly, nor whether they are both required for 
HGF-induced MET activity. Failure to understand the many 
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faces of these complex interactions prevents the rational design 
of molecularly targeted drugs that interfere with HGF-mediated 
receptor activation and tumor progression.
In order to unmask the domains of MET responsible for interac-
tion with HGF and to investigate their validity as therapeutic tar-
gets, we exploited a newly developed llama-based biotechnological 
platform that allows the production of human-like immunoglob-
ulins. By active immunization of outbred animals (Lama glama) 
with human tumor cells expressing high levels of the MET protein, 
we generated a large panel of antibodies that bind to human MET 
at high affinity. Using this panel, we screened for antibodies that 
competed with HGF for binding to MET and identified a highly 
diverse array of antagonistic molecules. Epitope mapping using 
human-llama MET chimeras unveiled that these HGF-displacing 
antibodies recognize hotspots localized within the SEMA domain 
and the IPT region. Interestingly, 1 of these hotspots is located 
within blades 2–3 of the β-propeller and coincides with the low-
affinity binding site for the HGF β chain (20). A second and a third 
hotspot are found within blade 5 of the β-propeller and within IPT 
domains 2–3, respectively, and coincide with the regions of MET 
where the α chain of HGF presumably binds according to indirect 
biochemical data (21, 22). A fourth and most represented hotspot 
is located across PSI and IPT 1, a region of MET not previously 
associated with HGF binding.
We show that antibodies directed against these hotspots 
inhibit HGF-induced MET activation and biological activity in 
biochemical and cellular assays. We also provide evidence that 
antibodies directed against the SEMA domain cooperate with 
antibodies directed against the IPT region in suppressing HGF-
dependent MET activity, confirming the hypothesis that mul-
tiple sites within the MET ECD are involved in HGF interaction. 
By showing that these antagonistic antibodies — alone and in 
combination — inhibit tumor progression in HGF-dependent, 
orthotopic mouse models of glioblastoma multiforme, triple-
negative mammary carcinoma, and metastatic colorectal cancer, 
we demonstrate that the hotspots identified in this study are 
valid targets for therapeutic intervention.
Results
Generation of HGF-competing anti-MET antibodies using a llama-based 
platform. In order to generate a large panel of antibodies directed 
against the extracellular portion of the human MET receptor in 
its native form, 6 llamas were immunized by intramuscular injec-
tion of 107 MKN-45 human gastric carcinoma cells, which display 
c-MET gene amplification and express very high levels of the MET 
protein (23). Animals were boosted weekly with the same amount 
of cells for 5 weeks (Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI72316DS1). 
Ten days after the last boost, blood samples were collected and 
total RNA was extracted from peripheral blood lymphocytes. The 
cDNAs encoding the VH-CH1 domains of llama IgG1 and the 
VL-CL domains (λ or κ) were amplified by PCR as described previ-
ously (24). PCR fragments were subcloned into the phagemid vec-
tor pCB3 that allows expression of recombinant antibodies as Fab 
fragments fused to the phage pIII envelope protein (25). Two phage 
libraries for each immunized animal were generated that contained 
a combination of immunoglobulin heavy chains with either λ- or 
κ-type light chains. The resulting 12 libraries were screened by pan-
ning of phages on an immobilized chimeric protein consisting of 
the MET ECD fused to the Fc portion of human IgG1 (MET-Fc). 
Two to four rounds of affinity selections were performed to enrich 
the libraries for phages displaying MET-specific Fabs. Individual 
colonies were isolated, and the Fab-containing periplasmic frac-
tion of each individual clone was directly analyzed for its abil-
ity to compete with HGF for binding to MET in an ELISA assay 
(Supplemental Figure 2). Clones that scored positive in this assay 
were sequenced in the VH and VL regions and divided into fami-
lies based on the VH CDR3 sequence. This procedure identified 
68 HGF-competing Fabs belonging to 32 different VH families 
(Supplemental Table 1). The specificity of these clones was further 
characterized by surface plasmon resonance using recombinant 
MET ECD in solid phase and the Fabs in soluble phase. The off-
rates (koff) of the various clones were in the range of 10–3 to 10–4 s–1.
Chimeric llama-human antibodies bind to human MET in ELISA and 
in living cells. From this panel of Fabs, we selected 13 clones belong-
Figure 1
Chimeric llama-human antibodies 
bind to human MET in ELISA. Binding 
of antibodies to MET was determined 
by ELISA using a purified human 
MET ECD protein in solid phase and 
increasing concentrations of the vari-
ous antibodies (0–20 nM) in solution. 
Antibody binding was revealed using 
secondary anti–human Fc antibodies 
conjugated with HRP. An irrelevant 
IgG1 was used as negative control. 
Data related to antibodies generated 
by different llamas are shown in sepa-
rate graphs.
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ing to 10 different VH families that displayed high HGF-displacing 
activity (in ELISA) and low off-rate (in surface plasmon resonance; 
Supplemental Figure 3A). The VH and VL regions of these Fabs 
were fused to human constant heavy chain domains (from IgG1) 
and a human constant light chain domain (κ or λ), respectively, 
generating chimeric llama-human mAbs (Supplemental Figure 3B). 
As controls, we also engineered 2 chimeric antibodies consisting of 
the same human constant domains fused to the murine variable 
regions of 5D5 (the bivalent progenitor of onartuzumab; ref. 26) 
and 224G11 (a humanized anti-MET antibody; ref. 27). As a nega-
tive control for binding specificity we used an irrelevant human 
IgG1. Chimeric antibodies were produced in a mammalian cell 
system, purified by protein A affinity chromatography, and tested 
by ELISA for their ability to bind to a purified human MET ECD 
(Figure 1). All antibodies tested bound to MET ECD with pico-
molar affinity (Table 1), displaying a Kd value ranging from 0.05 
nM (WT46) to 0.52 nM (WT4). Maximum binding capacity varied 
from antibody to antibody, suggesting that not all the epitopes rec-
ognized by these mAbs are equally available for binding, presum-
ably because of conformational heterogeneity of the recombinant 
MET ECD. ELISA binding assays using unrelated human tyrosine 
kinase receptors (macrophage-stimulating protein receptor, EGFR, 
PDGFR-α, VEGFR1), mouse MET, or llama MET unveiled that 
none of the 13 chimeric antibodies tested has a measurable affinity 
for any protein different from human MET (Supplemental Table 2). 
We also analyzed whether the same set of antibodies bound to MET 
in living cells. To this end, increasing concentrations of antibod-
ies (0–100 nM) were incubated with A549 human lung carcinoma 
cells, which express physiological levels of MET (28). Antibody 
binding to cells was analyzed by flow cytometry using anti–human 
Fc secondary antibodies. All antibodies displayed dose-dependent 
binding, indicating that they recognize membrane-bound MET in 
its native conformation (Figure 2).
Chimeric llama-human antibodies compete with HGF for binding to 
human MET. Next, we tested whether chimeric antibodies could 
compete with HGF for binding to MET in ELISA. To this end, 
immobilized MET-Fc was incubated with a fixed concentration 
of biotinylated HGF (0.3 nM) in the presence of increasing con-
centrations of chimeric antibodies (0–100 nM). HGF binding 
was revealed using streptavidin conjugated with HRP (Figure 3). 
Consistent with the screening strategy, this analysis revealed that 
all chimeric antibodies can displace HGF from MET, although 
with different potency and different efficacy (Table 1). In terms 
of potency, most antibodies achieved 50% HGF displacement at 
concentrations ranging from 0.07 nM (WT46) to 2.21 nM (WT15). 
Two antibodies were significantly less potent than the others 
(WT4, 4.98 nM; WT53, 28.18 nM). In terms of efficacy, only 7 
antibodies (WT5, WT14, WT37, WT38, WT46, WT52, WT60) 
achieved more than 90% HGF displacement at the maximal dose 
tested. To further examine the mutual competition between anti-
MET mAbs and HGF in a more biological context, we performed 
a mirror experiment in which A549 cells were incubated with a 
fixed concentration of the various antibodies (1 nM) in the pres-
ence of increasing concentrations of HGF (0–100 nM). Antibody 
binding was determined by flow cytometry as above. This analysis 
revealed that anti-MET antibody binding to cells is inversely pro-
portional to HGF concentration (Figure 4). In contrast, HGF did 
not affect binding of cetuximab, an anti-EGFR antibody. Notably, 
Table 1
Biochemical and biological properties of anti-MET antibodies
 Antibody MET binding HGF competition MET phosphorylation Cell scattering 
 Antagonistic  Agonistic  Antagonistic  Agonistic  
 activity activity activity activity
Clone Binding  K
d
 (nM) B
max
 (AU) IC
50
 (nM) E
max
 (%) IC
50
 (nM) E
max
 (%) % HGF  Score at  Max.  
 domain       activity 200 nM score
WT3 Blades 2–3 0.2 1.9 0.6 79.2 >200 20–25 40–50 1 0–1
WT4 IPT 2–3 0.5 0.8 5.0 60.2 >200 35–45 40–50 0 0–1
WT5 Blade 5 0.1 1.7 0.2 96.4 >200 40–50 65–70 1 2–3
WT14 PSI-IPT 1 0.1 1.5 0.1 96.2 2.9 60–70 20–25 1 0–1
WT15 PSI-IPT 1 0.2 1.5 2.2 86.6 3.3 70–80 35–40 2 2–3
WT25 IPT 2–3 0.1 1.1 1.3 63.6 5.4 50–65 20–25 1 0–1
WT26 IPT 2–3 0.3 1.1 0.8 69.4 6.3 65–75 40–45 2 2–3
WT37 Blades 1–2 0.1 1.8 0.4 90.3 38.0 50–55 15–20 1 0–1
WT38 PSI-IPT 1 0.1 1.4 0.2 92.3 >200 30–35 60–65 0 0–1
WT46 PSI-IPT 1 0.1 1.5 0.1 93.6 0.7 65–75 15–20 0 0–1
WT52 Blades 2–3 0.1 2.0 0.4 90.0 0.5 70–90 10–20 0 0–1
WT53 Blades 2–3 0.1 1.9 28.1 64.2 >200 5–10 15–20 3 0–1
WT60 PSI-IPT 1 0.1 1.5 0.2 92.4 0.9 60–70 15–20 1 0–1
Binding of anti-MET antibodies to MET was tested in ELISA using MET ECD in solid phase and mAbs in solution (see Figure 1). Binding affinity (Kd) and 
capacity (Bmax) were determined by nonlinear regression analysis. HGF competition was determined by ELISA using a MET-Fc chimera in solid phase and 
biotinylated HGF in solution (see Figure 3). Emax is the percent HGF displacement achieved by the highest mAb dose tested (200 nM). The ability of mAbs to 
inhibit HGF-induced MET phosphorylation (antagonistic activity) was analyzed using A549 cells (see Figure 6). Emax is the percent inhibition achieved by the 
highest mAb dose tested (200 nM). The ability of mAbs to promote MET phosphorylation in the absence of HGF (agonistic activity) was compared with that 
of recombinant HGF using A549 cells (see Supplemental Figure 6). Values correspond to percent maximal HGF activity. The ability of mAbs to inhibit HGF-
induced cell scattering (antagonistic activity) was determined using HPAF-II cells (see Figure 7) and is expressed using a scoring system ranging from 0 (no 
scatter) to 5 (maximal scatter; see Supplemental Figure 7). The ability of mAbs to promote cell scattering in the absence of HGF (agonistic activity) was also 
determined in HPAF-II cells and is expressed using the same scoring system (see Supplemental Figure 8). In the whole table, single values correspond to 
representative experiments. When substantial experimental variability was observed, the range of variation is shown instead.
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displacement of antibodies binding to MET with high affinity in 
both ELISA and FACS (e.g., WT38, WT46, WT52, WT60) required 
higher concentrations of HGF compared with other antibodies 
binding with lower affinity or avidity. Altogether, these results 
confirm that HGF and the chimeric mAbs compete for binding to 
the same target on living cells.
HGF-displacing mAbs recognize epitopes located throughout the MET 
ECD. In order to determine the epitopes recognized by HGF-
competing antibodies, we measured their binding to a panel of 
MET engineered proteins (Supplemental Figure 4A). This panel 
included: the entire MET ECD (Decoy MET); a MET ECD lacking 
IPT domains 3 and 4 (SEMA-PSI-IPT 1–2); a MET ECD lacking 
IPT domains 1–4 (SEMA-PSI); the isolated SEMA domain (SEMA); 
and a fragment containing IPT domains 3 and 4 (IPT 3–4). ELISAs 
using these engineered proteins indicated that the epitopes rec-
ognized by HGF-competing antibodies are distributed along the 
entire MET ECD (Supplemental Figure 4B). In fact, 5 antibodies 
(WT3, WT5, WT37, WT52, WT53) bound to the SEMA domain; 
5 antibodies (WT14, WT15, WT38, WT46, WT60) bound within 
the first 2 IPT domains; and 3 antibodies (WT4, WT25, WT26) 
bound to Decoy MET only, suggesting that they may recognize 
an epitope localized between IPT domains 2 and 3. The 5D5 and 
the 224G11 control antibodies bound to the SEMA and the first 2 
IPT domains, respectively. To more finely map these interactions, 
we exploited the absence of cross-reactivity between our antibod-
ies and llama MET (Supplemental Table 2). We generated a series 
of llama-human and human-llama chimeric MET proteins span-
ning the entire MET ECD (Supplemental Figure 5). Binding of 
Figure 2
Chimeric llama-human antibodies 
bind to human MET in living cells. 
A549 human lung carcinoma cells, 
which express physiological lev-
els of MET, were incubated with 
increasing concentrations of the 
indicated antibodies (0–100 nM). 
Antibody binding to cells was deter-
mined by flow cytometry using anti-
human secondary antibodies con-
jugated with phycoerythrin. CTX, 
cetuximab; IgG1, irrelevant IgG1.
Figure 3
Chimeric llama-human antibodies 
antagonize HGF binding to MET 
in ELISA. The ability of anti-MET 
antibodies to compete with bioti-
nylated HGF (0.3 nM) for binding 
to MET was analyzed by ELISA 
using MET-Fc in solid phase and 
increasing concentrations of chi-
meric antibodies (0–100 nM) in 
solution. HGF binding was revealed 
using HRP-conjugated streptavidin 
and expressed as percent rela-
tive to control (biotinylated HGF in 
the absence of mAbs). IgG1 is an 
irrelevant human antibody used as 
negative control.
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mAbs to chimeric MET was determined by ELISA. This analysis 
unveiled that 3 of the 5 SEMA-binding antibodies (WT3, WT52, 
WT53) recognize an epitope located within blades 2 and 3 (Sup-
plemental Table 3), precisely where the β chain of HGF binds at 
low affinity (20). The other 2 SEMA-binding antibodies recognize 
an epitope located within blades 1–2 (WT37) and blade 5 (WT5). 
All antibodies binding to SEMA-PSI-IPT 1–2 but not to SEMA-PSI 
(WT14, WT15, WT38, WT46, WT60) recognize an epitope located 
across the PSI domain and IPT domain 1. The 3 antibodies bind-
ing to Decoy MET only (WT4, WT25, WT26) recognize an epitope 
located across IPT domains 2 and 3. Finally, the 5D5 and 224G11 
control antibodies recognize an epitope located within blade 5 and 
IPT domain 1, respectively (see Figure 5A for a schematic represen-
tation). Interestingly, competition experiments revealed that anti-
bodies directed against PSI-IPT 1 interfere with 5D5 binding to 
MET, and antibodies directed against blade 5 (but not blades 1–3) 
interfere with 224G11 binding to MET (Supplemental Table 4). 
The same competition pattern was observed using mAbs and 
Fabs. Altogether, these results suggest a close spatial interaction 
between the SEMA domain and the IPT region, and are consistent 
with the hypothesis that HGF binds to multiple sites within the 
MET ECD (Figure 5B and refs. 18–22).
Chimeric llama-human anti-MET antibodies inhibit HGF-induced MET 
activation. The ability of HGF-competing antibodies to impair 
HGF-induced MET autophosphorylation was analyzed in A549 
human lung carcinoma cells, which represent a standard model 
for studying HGF-mediated biological activity (28). Cells were 
incubated for 24 hours in the absence of serum and then stimu-
lated with recombinant human HGF (1 nM) in the presence of 
increasing concentrations of chimeric mAbs (0–200 nM). The 
224G11 antagonistic antibody and an irrelevant IgG1 were used 
as positive and negative control, respectively. MET autophos-
phorylation was determined by ELISA using phospho-MET– 
specific antibodies (Figure 6). This analysis revealed that 8 anti-
bodies (WT14, WT15, WT25, WT26, WT37, WT46, WT52, WT60) 
strongly reduced HGF-induced MET phosphorylation, displaying 
Figure 4
Chimeric llama-human antibodies 
compete with HGF for binding onto 
human tumor cells. The ability of 
HGF to interfere with mAb binding to 
human tumor cells was determined 
by flow cytometry. A549 human lung 
carcinoma cells were incubated with 
a fixed concentration of the various 
antibodies (1 nM) in the presence of 
increasing concentrations of HGF 
(0–100 nM). Antibody binding to 
cells was determined by flow cytom-
etry using phycoerythrin-conjugated 
anti-human secondary antibodies 
and expressed as percent relative to 
control (1 nM HGF in the absence of 
antibodies). Cetuximab (CTX) was 
used as a negative control.
Figure 5
Schematic representation of the extracellular domain of MET and its 
interactions with HGF. (A) Representations of the hotspots identified 
by the HGF-competing antibodies described in this study. The corol-
la represents the 7-bladed β-propeller of the semaphorin homology 
domain (SEMA); single petals represent blades 1–7 (b1–b7). The 
flower bud represents the plexin-semaphorin-integrin homology 
domain (PSI). The leaves on the stalk represent immunoglobulin-
plexin-transcription factor homology domains 1–4 (IPT 1–4). The 
red symbols indicate the localization of the epitopes recognized by 
the different antibodies. (B) Hypothetical model of HGF-MET inter-
actions. The bee represents HGF, the abdomen being the α chain 
and the thorax and head being the β chain. The β chain interacts 
with SEMA blades 1–3; the α chain interacts with SEMA blade 5 on 
one end and with IPT 2–3 on the other. It is not clear whether the 
α chain interacts with PSI-IPT 1 as well or is just positioned close 
to them. This model is based on a synthesis of our results related 
to the localization of the epitopes recognized by HGF-competing 
antibodies with the data available in the literature (18–22).
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50%–90% inhibition of HGF activity at the maximal concentra-
tion tested (Table 1). Four antibodies (WT3, WT4, WT5, WT38) 
displayed reduced inhibitory activity (20%–50%). Consistent with 
its weak HGF-displacing ability (Figures 3 and 4), WT53 did not 
significantly inhibit HGF-induced MET autophosphorylation 
(5%–10%). Since the bivalent structure of antibodies can stabilize 
receptor dimers, thus resulting in receptor activation (29), we also 
investigated whether our mAbs induced HGF-independent MET 
autophosphorylation. To this end, we performed an analogous 
MET autophosphorylation assay stimulating cells with increas-
ing concentrations (0–200 nM) of antibodies in 
the absence of HGF. As a positive control for MET 
activation we used HGF and the 5D5 antibody, 
which is known to display agonistic activity in its 
bivalent form (30). Cells were processed for ELISA 
as described above, and the agonistic activity of 
mAbs was expressed as percent maximal HGF 
activity (Table 1 and Supplemental Figure 6). This 
analysis revealed that 7 antibodies (WT14, WT25, 
WT37, WT46, WT52, WT53, WT60) displayed a 
minor agonistic effect that never exceeded 25% of 
maximal HGF activity at any concentration test-
ed. Four antibodies (WT3, WT4, WT15, WT26) 
induced intermediate MET autophosphorylation 
(35%–50%), and only 2 (WT5, WT38) matched the 
agonistic activity of 5D5 (60%–70%).
Chimeric llama-human anti-MET antibodies inhibit HGF-induced cell 
scattering. To evaluate whether chimeric anti-MET antibodies could 
affect HGF-dependent biological activity, we tested their ability to 
inhibit HGF-induced cell scattering. HPAF-II human pancreatic 
adenocarcinoma cells (31) were stimulated with increasing con-
centrations of HGF (0–1.1 nM), and cell scattering was determined 
20 hours later by microscopy. This preliminary analysis revealed 
that HGF-induced cell scattering is linear until it reaches satura-
tion at a concentration of 0.14 nM. To quantify scatter activity, we 
elaborated a scoring system based on a standard HGF curve rang-
Figure 6
Chimeric llama-human antibodies 
inhibit HGF-induced MET autophos-
phorylation. A549 human lung car-
cinoma cells were stimulated with 
recombinant human HGF (1 nM) 
in the presence of increasing con-
centrations of chimeric mAbs 
(0–200 nM). The 224G11 antibody 
and an irrelevant IgG1 were used 
as positive and negative control, 
respectively. MET autophosphoryla-
tion was determined by ELISA using 
phospho-MET–specific antibodies 
and is expressed as percent relative 
to control (1 nM HGF in the absence 
of antibodies).
Figure 7
Chimeric llama-human antibodies inhibit HGF-
induced cell scattering. HPAF-II human pancreatic 
adenocarcinoma cells were stimulated with 0.14 nM 
HGF in the presence of increasing concentrations 
of antibodies (0, 7.4, 22, 67, 200 nM). Scatter activity 
was determined 24 hours later by microscopy using a 
scoring system based on a standard HGF curve (0, 
total absence of cell scattering; 5, maximal cell scat-
tering; see text and Supplemental Figure 7).
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ing from 0 (total absence of cell scattering in the absence of HGF) 
to 5 (maximal cell scattering in the presence of 0.14 nM HGF; Sup-
plemental Figure 7). We then incubated cells with 0.14 nM HGF in 
the presence of increasing concentrations of antibodies (0, 7.4, 22, 
67, 200 nM) and determined scatter activity using the scoring sys-
tem described above. The antagonistic anti-MET antibody 224G11 
was used as a positive control. Results are shown in Figure 7. Four 
antibodies (WT4, WT38, WT46, WT52) potently inhibited HGF-
induced cell scattering in a dose-dependent fashion, resulting in 
complete neutralization of scatter activity at the highest concentra-
tion tested (200 nM; score = 0). Six antibodies (WT3, WT5, WT14, 
WT25, WT37, WT60) also inhibited HGF-induced cell scattering, 
although they could not fully neutralize it at the highest concentra-
tion tested (200 nM; score = 1). The remaining antibodies (WT15, 
WT26, WT53) showed only a partial inhibitory activity. Next, we 
tested whether our antibodies displayed agonistic activity by induc-
ing HGF-independent cell scattering. To this end, we stimulated 
HPAF-II cells with increasing concentrations of mAbs (0, 7.4, 22, 
67, 200 nM) in the absence of HGF. The agonistic antibody 5D5 
was used as a positive control. Scatter activity was quantified using 
the scoring system described above. Results are shown in Supple-
mental Figure 8. Only 3 mAbs (WT5, WT15, WT26) induced cell 
scattering to an extent comparable to 5D5. The remaining antibod-
ies displayed no or marginal scatter activity (score = 0–1) at low con-
centrations but were inactive at higher doses.
Concomitant targeting of the SEMA and IPT regions results in coopera-
tive inhibition of HGF-dependent activity. We systematically analyzed 
the results obtained in phosphorylation and scatter assays search-
ing for antibodies that displayed potent antagonistic properties 
(maximal MET inhibition >50%; scatter score at maximal mAb 
concentration ≤1) and weak agonistic activity (percent HGF activ-
ity ≤25%; maximal scatter score ≤1). This analysis identified 6 
antibodies binding to different MET regions (WT37 and WT52, 
SEMA; WT14, WT46, and WT60, PSI-IPT 1; WT25, IPT 2–3; 
Table 1). In order to explore a possible cooperative effect result-
ing from simultaneous targeting of different domains, we tested 
multiple antibody pairs in biochemical and biological assays. The 
2 SEMA-binding mAbs recognize 2 close but distinct epitopes 
located within blades 1–2 and 2–3, respectively. The 3 PSI-IPT 1–
binding mAbs recognize either the same epitope or closely asso-
ciated epitopes located across PSI and IPT 1. Among the latter 
antibodies, WT46 was selected because of its higher affinity and 
superior performance (Table 1). Cooperation was investigated by 
testing of all possible antibody pairs (WT37-WT52, WT37-WT46, 
WT37-WT25, WT52-WT46, WT52-WT25, WT46-WT25) in both 
phosphorylation and scatter experiments. In all assays, increasing 
concentrations (0–200 nM) of single mAbs were compared with 
equal concentrations of a 1:1 mixture of 2 different mAbs (i.e., 200 
nM of either mAb 1 or mAb 2 is compared with 100 nM of mAb 
1 + 100 nM of mAb 2). For each combination, we evaluated its 
ability to (a) inhibit HGF-mediated MET autophosphorylation 
(Supplemental Figure 9); (b) inhibit HGF-induced cell scattering 
(Supplemental Figure 10); (c) promote MET autophosphorylation 
in the absence of HGF (Supplemental Figure 11); and (d) promote 
cell scattering in the absence of HGF (Supplemental Figure 12). 
This analysis revealed that simultaneous targeting of the SEMA 
and IPT regions of MET resulted in enhanced inhibition of HGF-
induced MET autophosphorylation (Table 2). However, only the 
WT52-WT46 combination resulted in a significantly improved 
antagonistic activity in scatter assays. No obvious advantage was 
achieved by any antibody combination in terms of agonistic activ-
ity, which actually appeared to increase in the WT37-WT25 and 
WT52-WT25 pairs. Remarkably, in both antagonism and ago-
nism, cooperation in biochemical activity (phosphorylation) did 
not necessarily mirror cooperation in biological activity (scatter). 
This phenomenon is likely to reflect the possibility that other fac-
tors in addition to receptor tyrosine phosphorylation may also 
contribute to determining biological activity, including receptor 
internalization dynamics, duration of the signal, and differential 
activation of signaling pathways. Among the antibody combina-
tions tested, the only 1 that coherently displayed a significant 
advantage over the corresponding single antibodies in both the 
assays was the WT52-WT46 pair.
The WT52 and WT46 antibodies cooperate in inhibiting HGF-mediated 
invasive growth. Combination of WT52 (directed against SEMA 
blades 2–3) and WT46 (directed against the PSI-IPT 1 domains) 
Table 2
Concomitant targeting of the SEMA and IPT regions results in cooperative inhibition of HGF-dependent MET activity
 Binding domain SEMA blade 1 SEMA blades 2–3 PSI-IPT 1 IPT 2–3
 Antibody WT37 WT52 WT46 WT25 
 Assay type Phospho Scatter Phospho Scatter Phospho Scatter Phospho Scatter
Combination with:
 WT37 54% 5 71% 3 85%A 4 70%A 4
 WT52 – – 76% 3 96%A  1A 85%A  4
 WT46 – – – – 70% 4 62% 3
 WT25 – – – – – – 57% 3
Cooperation between different antibodies was analyzed in receptor phosphorylation assays (Phospho) and cell scattering assays (Scatter). In phosphoryla-
tion assays, A549 cells were stimulated with recombinant HGF (1 nM) in the presence of increasing concentrations (0–200 nM) of single mAbs or a 1:1 
mixture of 2 different mAbs. MET autophosphorylation was determined by ELISA using anti–phospho-MET antibodies. Antagonistic activity is expressed 
as percent inhibition at the maximal mAb dose tested (200 nM). Percent inhibition is relative to the corresponding concentration of irrelevant IgG1. In scatter 
assays, HPAF-II cells were stimulated with recombinant HGF (0.14 nM) in the presence of increasing concentrations (0–200 nM) of single mAbs or a 1:1 
mixture of 2 different mAbs as above. Cell scattering was determined by microscopy and quantified using a scoring system ranging from 0 (no scatter) to 5 
(maximal scatter). Since cooperation in scattering is manifest at low antibody concentrations, antagonistic activity is expressed as the score observed at the 
lowest antibody dose tested (7.4 nM) and not at the highest (200 nM) as in Table 1. Data are related to the representative experiments shown in Supplemen-
tal Figure 10 (phosphorylation) and Supplemental Figure 12 (scatter). Note that inhibition of MET tyrosine activity did not always result in inhibition of cell 
scattering activity (see text). AValues corresponding to combinations that perform better compared with both the respective single antibodies.
Downloaded October 14, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI72316.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 7   July 2014 3179
resulted in both increased efficacy and higher potency. In bio-
chemical assays, complete inhibition of HGF-induced MET auto-
phosphorylation was reached at a dose of 12.5 nM (6.25 nM 
WT52 + 6.25 nM WT46), while neither of the 2 mAbs, when used 
as single agents, could fully antagonize MET activation even at 
the highest concentration tested (Figure 8A). In biological assays, 
combination of WT52 and WT46 achieved a high degree of inhibi-
tion (score = 1) already at the lowest concentration tested (7.4 nM; 
3.7 nM WT52 + 3.7 nM WT46), and completely suppressed HGF-
induced cell scattering at a dose of 67 nM (33.5 nM + 33.5 nM; 
Figure 8B). Based on these results, cooperation between WT52 
and WT46 was further tested in a real-time cell motility assay 
using an xCELLigence real time cell analyzer (RTCA). HGF-depen-
dent HPAF-II cell motility was expressed as normalized cell index. 
Remarkably, while both WT52 and WT46 alone inhibited HGF-
induced motility by approximately 50%, 
the combination of WT52 plus WT46 
achieved complete neutralization of 
HGF activity (Figure 8C). We also tested 
the WT52-WT46 combination in an 
anchorage-independent cell growth assay. 
A549 cells were seeded in soft agar in the 
presence of 0.34 nM HGF and treated 
twice weekly either with single antibodies 
(200 nM) or with a 1:1 antibody combi-
nation (100 nM + 100 nM). An irrelevant 
IgG1 was used as negative control. After 
3 weeks, cell colonies were stained with 
tetrazolium salts, photographed, and 
quantified using dedicated software. In 
these conditions, WT52 and WT46 alone 
inhibited colony formation by approxi-
mately 68% and 67%, respectively, while 
their combination completely prevented 
HGF-induced anchorage-independent 
cell growth (Figure 8D).
Anti-MET antibodies inhibit tumor growth 
in an HGF-dependent human xenograft model. 
Prompted by the above results, we ana-
lyzed the ability of WT52 and WT46 to 
interfere with HGF-dependent tumor pro-
gression in mouse models of cancer. Since 
mouse HGF binds to human MET with 
low affinity and fails to activate it (32), 
testing the therapeutic potential of HGF-
competing antibodies in mice requires a 
source of human HGF. The most charac-
terized HGF-dependent xenograft model 
is represented by U87-MG human glioma 
cells, which express both MET and HGF 
(30). We performed a series of prelimi-
nary experiments using different doses 
of WT52 and WT46 (0.3, 1, 3, 10, and 30 
mg/kg) in NOD-SCID mice bearing U87-
MG xenografts (Supplemental Figure 13). 
On the basis of this preliminary analysis, 
we decided to continue testing antibody 
activity at a dose of 10 mg/kg. To this end, 
U87-MG cells were injected s.c. into NOD-
SCID mice. After approximately 4 weeks, 
mice were stratified on the basis of tumor volume and divided into 
4 homogeneous groups (n = 5), which were randomly assigned 
to the following treatment arms: irrelevant IgG1 (10 mg/kg); 
WT52 (10 mg/kg); WT46 (10 mg/kg); and a combination of 
WT52 and WT46 (5 + 5 mg/kg). Antibodies were administered 
twice weekly by i.p. injection, and tumor growth was followed over 
time by caliper measurement. Mice were sacrificed when tumor 
volume reached 2,000 mm3. This experiment revealed that while 
both WT46 and WT52 significantly inhibited U87-MG xeno-
graft growth compared with control, their combination was more 
effective (Figure 9A). The experiment was stopped after 5 weeks 
of treatment, and mouse survival was assessed by Kaplan-Meier 
analysis (Figure 9B). All animals in the control group had to be 
sacrificed before or by the third week of treatment. In contrast, by 
the end of the experiment, only 3 and 4 mice had been sacrificed 
Figure 8
WT52 and WT46 cooperate in inhibiting HGF-mediated invasive growth. (A) Inhibition of HGF-
induced MET autophosphorylation. A549 cells were stimulated with 1 nM recombinant HGF in 
the presence of increasing concentrations (0–200 nM) of WT52, WT46, or a 1:1 mixture of WT52 
and WT46 (i.e., 200 nM of either WT52 or WT46 is compared with 100 nM of WT52 + 100 nM of 
WT46). An irrelevant IgG1 was used as negative control. MET autophosphorylation was deter-
mined by ELISA and is expressed as percent relative to control. (B) Inhibition of HGF-induced cell 
scattering. HPAF-II cells were stimulated with 0.14 nM HGF in the presence of increasing con-
centrations (0–200 nM) of antibodies as in A. Scatter activity was determined by microscopy and 
is expressed using the scoring system described in the text (0, total absence of cell scattering; 
5, maximal cell scattering). (C) Inhibition of HGF-induced cell motility. HPAF-II cells were preincu-
bated with 200 nM WT52, 200 nM WT46, or 100 nM WT52 + 100 nM WT46 and then stimulated 
with 0.14 nM HGF. Cell motility was monitored in real time using an xCELLigence RTCA device 
and is expressed as normalized cell index. (D) Inhibition of HGF-induced anchorage-independent 
cell growth. A549 cells were grown in soft agar in the presence of 0.34 nM HGF plus 200 nM anti-
bodies as in C. Colony growth was determined after 2 weeks as described in the text. Statistical 
significance was determined by a Student’s t test (n = 4).
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in the WT52 and WT46 groups, respectively. In the combination 
group, all mice survived until termination of the experiment. In a 
similar set of experiments aimed at assessing the in vivo specific-
ity of antibodies, we injected NOD-SCID mice s.c. with 2 distinct 
human tumor cell lines not expressing MET at both the mRNA 
and the protein level (TOV-112D and A2780 ovarian carcinoma 
cells; refs. 28, 33). Tumor-bearing animals were randomized and 
assigned to 3 treatment arms (irrelevant IgG1, 10 mg/ml; WT52, 
10 mg/ml; WT46, 10 mg/ml; n = 6). Antibodies were administered 
twice weekly by i.p. injection, and tumor volume was followed over 
time as above. As no statistically significant difference could be 
observed between any of the experimental groups tested, we con-
clude that the antitumor activity of WT52 and WT46 is strictly 
MET-dependent (Supplemental Figure 14).
Anti-MET antibodies prolong survival in an orthotopic mouse model of 
glioblastoma multiforme. The pharmacological effect of WT52 and 
WT46 on U87-MG glioma cells was further analyzed in an ortho-
topic model. Luciferase-expressing U87-MG cells were microinject-
ed into the nucleus caudatus/putamen of CD-1 nude mice using 
a stereotaxic apparatus. After approximately 2 weeks, mice were 
stratified based on in vivo bioluminescence signal, and assigned to 
4 treatment arms (IgG1, WT52, WT46, WT52 + WT46; n = 6). Anti-
bodies were administered twice weekly by i.p. injection with the 
same dosage used in the s.c. experiment. Mice were sacrificed when 
showing manifest neurological symptoms, and the experiment 
was stopped after 8 weeks of treatment. As assessed by whole-body 
bioluminescence analysis, both single antibodies and their combi-
nation significantly delayed orthotopic tumor growth compared 
with control (Figure 10A). Kaplan-Meier analysis of experimental 
data revealed that all antibody treatments were associated with 
Figure 9
Anti-MET antibodies inhibit tumor growth in an HGF-dependent human 
xenograft model. U87-MG human glioma cells, which express both 
MET and HGF, were injected s.c. into NOD-SCID mice. Mice were 
stratified on the basis of tumor volume and randomly assigned to 4 
treatment arms (irrelevant IgG1, 10 mg/kg; WT52, 10 mg/kg; WT46, 
10 mg/kg; a combination of WT52 and WT46, 5 + 5 mg/kg; n = 5). 
Antibodies were administered twice weekly by i.p. injection, and tumor 
growth was followed over time by caliper measurement. Mice were sac-
rificed when tumor volume overrode 2,000 mm3. (A) Analysis of tumor 
volume over time. Average tumor volume was calculated for each arm 
until all mice in a given group were alive. Statistical significance was 
determined by a Student’s t test. (B) Kaplan-Meier analysis of mouse 
survival. Statistical significance was determined using a log rank test. 
See also Supplemental Figure 13 for dose escalation experiments.
Figure 10
Anti-MET antibodies prolong survival in an orthotopic mouse model of 
glioblastoma multiforme. U87-MG human glioma cells engineered to 
express luciferase were injected into the nucleus caudatus/putamen 
of CD-1 nude mice using a stereotaxic apparatus. Mice were stratified 
on the basis of in vivo bioluminescence and randomly assigned to 4 
treatment arms (irrelevant IgG1, 10 mg/kg; WT52, 10 mg/kg; WT46, 
10 mg/kg; a combination of WT52 and WT46, 5 + 5 mg/kg; n = 6). 
Antibodies were administered by i.p. injection twice weekly. (A) Tumor 
growth over time as assessed by whole-body bioluminescence analy-
sis. Average tumor bioluminescence, expressed as photons per sec-
ond (p/s), was calculated for each arm until all mice in a given group 
were alive. Statistical significance was determined by a Student’s t test. 
(B) Kaplan-Meier analysis of mouse survival. Statistical significance 
was determined using a log rank test.
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increased mouse survival (Figure 10B). However, in contrast to the 
s.c. setting, in which both antibodies displayed comparable activ-
ity, WT52 performed better than WT46 in this model. Consistent 
with this, combination of WT52 and WT46 was significantly more 
effective than WT46 alone, but it only showed a trend toward 
benefit compared with WT52. Immunohistochemical analysis of 
brain sections using anti–human Fc antibodies revealed compa-
rable levels of WT52 and WT46 within the tumor, thus suggesting 
that this difference may not be due to increased tumor penetration 
by WT52 (Supplemental Figure 15A). We hypothesize that the 2 
epitopes recognized by WT52 and WT46 are not equally available 
in the orthotopic setting, or that they play different roles in dis-
ease progression. Consistent with a role of HGF/MET signaling 
in glioblastoma invasion, histological analysis of brain sections 
revealed that all antibody-treated tumors appeared more encapsu-
lated compared with controls and displayed a less invasive tumor-
parenchyma border (Supplemental Figure 15B).
Neoadjuvant therapy with anti-MET mAbs reduces metastasis dissemi-
nation in a mouse model of orthotopic mammary carcinoma. Recent 
studies point at a role of HGF/MET signaling in the progression 
of triple-negative breast cancer (34, 35). To explore the therapeu-
tic potential of anti-MET antibodies in this setting, we set up an 
orthotopic model of metastatic mammary carcinoma in which 
human HGF is provided paracrinally by stromal cells. Tumor 
growth and metastatic dissemination in this model are depen-
dent on HGF-induced MET activation, as they can be inhibited by 
anti–human HGF neutralizing antibodies (Supplemental Figure 
16). Luciferase-expressing MDA-MB-231 human triple-negative 
mammary carcinoma cells were injected bilaterally into the mam-
mary fat pad of immunodeficient NOD-SCID mice along with 
HGF-secreting, immortalized human mammary fibroblasts (36). 
After 2 weeks, mice were stratified on the basis of tumor volume 
and randomly assigned to 5 different treatment groups (n = 6), 
including the 4 antibody arms described above (IgG1, 10 mg/kg; 
WT52, 10 mg/kg; WT46, 10 mg/kg; WT52 + WT46, 5 + 5 mg/kg) 
and 1 additional arm testing a small-molecule MET tyrosine 
kinase inhibitor (JNJ-38877605, 20 mg/kg; refs. 37, 38). Antibod-
ies were administered twice weekly by i.p. injection; JNJ-38877605 
was administered daily by oral gavage. Tumor volume was fol-
lowed over time by caliper measurement. After 4 weeks of treat-
ment, tumors were surgically removed, and neoadjuvant therapy 
was interrupted. Two weeks after surgery, mice were injected 
with luciferin, sacrificed, and subjected to autopsy. Metastatic 
dissemination was determined by bioluminescence analysis of 
isolated lungs. This analysis revealed that both WT46 and WT52 
significantly reduced tumor burden (Figure 11A) and pulmonary 
metastases (Figure 11B) compared with controls. Combination of 
the 2 antibodies was more effective than either single antibodies 
or JNJ-38877605 in reducing both tumor growth and metastasis, 
and this difference was statistically significant. Congruent results 
were obtained in an analogous experiment that employed 5 mice 
per group (not shown).
Figure 11
Neoadjuvant therapy with anti-MET mAbs reduc-
es metastasis dissemination in a mouse model 
of orthotopic mammary carcinoma. Luciferase-
expressing MDA-MB-231 human triple-negative 
mammary carcinoma cells were injected bilater-
ally into the mammary fat pad of immunodefi-
cient NOD-SCID mice along with HGF-secret-
ing, immortalized human mammary fibroblasts. 
Mice were stratified on the basis of tumor vol-
ume and randomly assigned to 5 different treat-
ment groups (irrelevant IgG1, 10 mg/kg; WT52, 
10 mg/kg; WT46, 10 mg/kg; a combination of 
WT52 and WT46, 5 + 5 mg/kg; JNJ-38877605, 
20 mg/kg; n = 6). Antibodies were administered 
twice weekly by i.p. injection; JNJ-38877605 was 
administered daily by oral gavage. Tumor volume 
was followed over time by caliper measurement. 
After 4 weeks of treatment, tumors were surgi-
cally removed, and neoadjuvant therapy was 
interrupted. Two weeks after surgery, mice were 
injected with luciferin, sacrificed, and subjected 
to autopsy. Metastatic dissemination was deter-
mined by bioluminescence analysis of isolated 
organs. (A) Analysis of tumor volume over time. 
Statistical significance was calculated by a 
Student’s t test (n = 12). (B) Bioluminescence 
analysis of isolated lungs at autopsy. Red bars 
indicate average values. Statistical significance 
was determined as in A (n = 6). (C) Representa-
tive images of lung sections stained with H&E. 
Original magnification, ×100. The data shown 
are derived from a representative experiment. 
An analogous experiment conducted with 5 mice 
per group generated overlapping results.
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Anti-MET mAbs display antitumor and antimetastatic activity in a 
KRAS-mutant orthotopic mouse model of colon carcinoma. Paracrine 
HGF secretion by myofibroblasts in the tumor microenvironment 
plays a key role in the survival, growth, and invasion of colorec-
tal carcinoma cells (39, 40). To test whether anti-MET antibodies 
could interfere with this process, we set up an orthotopic model 
of metastatic colorectal carcinoma that resembles the environ-
mental conditions found in human cancer (41). Briefly, luciferase- 
expressing human colorectal carcinoma cells are microinjected 
into the cecum submucosa of immunodeficient mice along with 
immortalized, HGF-secreting human colon myofibroblasts. 
Tumors in the cecum develop within a few days after cell injection 
and reproduce the pattern of metastatic dissemination observed 
in the clinic (Supplemental Figure 17A). Metastases can be con-
veniently detected by bioluminescence analysis of isolated organs 
(Supplemental Figure 17B). Myofibroblasts persist at the tumor 
site for the whole duration of the experiment (Supplemental Fig-
ure 17C). Experimental evidence indicates that orthotopic tumor 
growth and metastatic dissemination is HGF-dependent in this 
system (Supplemental Figure 17, D and E). To test the therapeutic 
potential of the WT52 and WT46 antibodies, we microinjected a 
3:1 mix of luciferase-expressing, KRAS-mutant HCT-116 human 
colorectal carcinoma cells and human colon myofibroblasts into 
the cecum of NOD-SCID mice. One week after cell injection, mice 
were stratified on the basis of in vivo bioluminescence and ran-
domly assigned to 4 treatment arms (n = 7) as described above 
(IgG1, 10 mg/kg; WT52, 10 mg/kg; WT46, 10 mg/kg; a combina-
tion of WT52 and WT46, 5 + 5 mg/kg). Treatment continued for 
4 weeks, and tumor growth was followed over time by total-body 
bioluminescence examination. This analysis revealed that while 
both antibodies significantly reduced tumor growth compared 
with control, their combination was significantly more effec-
tive (Figure 12A). At the end of the treatment, mice were sacri-
ficed and subjected to autopsy. Bioluminescence analysis of liver 
explants revealed that both WT46 and WT52, alone or in com-
bination, dramatically reduced metastatic dissemination com-
pared with control (Figure 12, B and C). Combination of WT52 
and WT46 reduced metastatic dissemination significantly more 
effectively than single antibodies. Similar results were obtained in 
an analogous experiment conducted independently using 5 mice 
per group (not shown).
Discussion
In this study we exploited a newly developed antibody platform 
to identify a large panel of antagonistic antibodies that compete 
with HGF for binding to MET. The high diversity of this panel 
unveiled that HGF-competing antibodies recognize epitopes 
clustering in several hotspots that are distributed throughout 
the MET ECD. This finding is consistent with the idea that the 
interaction between HGF and MET is very complex and involves 
multiple binding sites located within different domains of both 
the ligand and the receptor.
Figure 12
Anti-MET mAbs display antitumor and 
antimetastatic activity in an orthotopic 
mouse model of KRAS-mutant colon 
carcinoma. A 3:1 mix of luciferase-
expressing, KRAS-mutant HCT-116 
human colorectal carcinoma cells and 
HGF-secreting human colon myofi-
broblasts were microinjected into the 
cecum submucosa of NOD-SCID 
mice. One week after cell injection, 
mice were stratified on the basis of in 
vivo bioluminescence and randomly 
assigned to 4 treatment arms (irrele-
vant IgG1, 10 mg/kg; WT52, 10 mg/kg; 
WT46, 10 mg/kg; a combination of 
WT52 and WT46, 5 + 5 mg/kg; n = 7). 
Tumor growth was followed over time 
by total-body bioluminescence exami-
nation. After 4 weeks, mice were sac-
rificed and subjected to autopsy. (A) 
Tumor growth over time as assessed 
by whole-body bioluminescence. Sta-
tistical significance was calculated 
by a Student’s t test. (B) Analysis of 
liver metastases as assessed by bio-
luminescence analysis of explanted 
organs. Statistical significance was 
calculated as in A. (C) Representative 
images from an independent experi-
ment conducted in the same condi-
tions showing luciferase signal of 
explanted livers.
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The hotspots identified by our HGF-competing antibodies pro-
vide useful hints for unraveling the complexity of HGF-MET inter-
action. The only molecularly detailed information about HGF bind-
ing to MET derives from the crystal structure of the HGF β chain 
in complex with the MET SEMA domain. These crystallographic 
data indicate that the pseudocatalytic pocket of the serine protease-
like domain of HGF β chain interacts with the “bottom” face of the 
SEMA β-propeller, forming contacts with blades 2–3 (20). Interest-
ingly, 1 of the hotspots identified by our antibodies (WT3, WT52, 
WT53) precisely coincides with this region of MET (Figure 5A), thus 
validating the accuracy of our system in predicting HGF-MET inter-
actions and providing effective tools for targeting this crucial inter-
face. A second hotspot, recognized by 1 of our antibodies (WT5) and 
by a control antibody (5D5), localizes within blade 5 of the SEMA 
β-propeller. A recent crystallographic study on onartuzumab, the 
1-armed version of 5D5, confirms that this antibody forms contact 
with blade 5 and shows that it competes with the α chain of HGF — 
but not with the β chain — for binding to MET (21). Taken together, 
these results support a model in which HGF binds to blades 2–3 via 
the β chain and to blade 5 via the α chain (Figure 5B).
However, the data presented in this study suggest that this pic-
ture is not complete. In fact, our antibody-based approach iden-
tifies a third and a fourth hotspot that add complexity to the 
above model. The third hotspot localizes within IPT domains 2–3, 
a region of MET previously proposed to contain a high-affinity 
binding site for the α chain of HGF (22). The finding that anti-
bodies directed against IPT domains 2–3 (WT4, WT25, WT26) 
compete with HGF for binding to MET supports this hypothesis 
and suggests that HGF α chain forms multiple interfaces with its 
receptor (with SEMA blade 5 on one side and with the IPT region 
on the other). This scenario is further complicated by the finding 
that the fourth and most represented hotspot is located within 
PSI and IPT domain 1, a region of MET not previously associated 
with binding to HGF. It is not clear whether antibodies binding to 
this hotspot displace HGF directly (by binding to the same site) or 
indirectly (by steric hindrance or allosteric modification). Interest-
ingly, we observed that antibodies (mAbs or Fabs) directed against 
PSI-IPT 1 (WT14, WT15, WT38, WT46, WT60, 224G11) compete 
for binding to MET with antibodies directed against SEMA blade 5 
(and vice versa), but not with antibodies directed against blades 
1–3 or IPT 2–3 (Supplemental Table 3). These observations sug-
gest that SEMA blade 5 and the PSI-IPT 1 region come in close 
proximity despite their distance from a primary structure view-
point (Figure 5A). This hypothesis is consistent with the 3D data 
emerging from the crystal structure of the MET ECD in complex 
with the bacterial protein internalin B (42). Considering that all 
antibodies binding to any of the hotspots described here compete 
with HGF for binding to MET, these results support a model in 
which the SEMA domain and the IPT region of MET are leaned 
toward each other using the PSI domain as a hinge in a fashion 
similar to that of plexins (43) and forming a pocket into which 
the HGF α chain fits. In this model, the HGF β chain remains 
excluded from the pocket and interacts with SEMA blades 2–3, 
while the α chain forms contact with SEMA blade 5 on one side 
and with IPT domains 2–3 on the other (Figure 5B). Since there is 
no evidence for HGF binding directly to PSI-IPT 1 (22), we hypoth-
esize that antibodies directed against this region of MET could 
recognize an allosteric epitope located across the PSI and IPT 1 
domains, thus locking the pocket in a conformation that is not 
prone to accommodate the α chain. In support of this hypothesis, 
surface plasmon resonance experiments suggest that WT46 binds 
at low affinity to either PSI or IPT 1, but at high affinity to PSI-IPT 
1 (data not shown). Further studies are warranted to elucidate the 
mechanism underlying HGF α chain binding to MET.
The complexity of HGF-MET interaction unveiled by our analy-
sis provides a rationale for explaining why simultaneous targeting 
of different MET domains with antagonistic antibodies achieves 
a cooperative effect. The results obtained in receptor autophos-
phorylation assays and cell scattering assays indicate that antibod-
ies binding to the SEMA domain (blade 1 or blades 2–3) cooper-
ate with antibodies directed against the IPT region (PSI-IPT 1 or 
IPT 2–3) in inhibiting HGF-induced biochemical and biological 
activity. However, blade 1 binders did not cooperate with blade 
2–3 binders, and IPT 2–3 binders did not cooperate with PSI-IPT 1 
binders (Supplemental Figures 9–12). With reference to the model 
proposed above, these data are congruent with the idea that HGF 
α chain cooperates with HGF β chain in activating MET (19) and 
that, in order to fully antagonize HGF activity, both these interac-
tions must be blocked. Interestingly, the most effective cooperation 
was achieved combining WT52 (a blade 2–3 binder) with WT46 (a 
PSI-IPT 1 binder). According to the model proposed, this combina-
tion would result in displacement of HGF β chain on one hand and 
in conformational disruption of the α chain–harboring pocket on 
the other (Figure 5B). The finding that a significant fraction (5/13) 
of the HGF-displacing antibodies identified binds within the PSI-
IPT 1 region supports the idea that this previously unidentified 
pocket, generated by bending of the SEMA domain over the IPT 
region, plays a key role in determining HGF-MET interaction and 
represents a strategic target for therapeutic intervention.
Although cooperation between antibodies directed against 
different MET domains was reproducibly observed in vitro in a 
variety of biochemical and biological assays, the WT52 and WT46 
antibodies did not always show a sound synergistic effect in mice. 
This discrepancy may be due to the fact that achieving equal tar-
get engagement is not always granted in vivo. In fact, cooperation 
between 2 different antibodies requires both molecules to be on 
target at the same time at similar concentrations. This condition 
can be obtained without difficulty in cultured cells, but in tissues, 
where antibody concentration depends on a plethora of indepen-
dent parameters including plasma stability, vessel permeability, 
drug diffusion, tissue penetration, and protein turnover, the local 
concentration of 2 distinct mAbs can vary significantly. More-
over, many environmental factors, including secreted cytokines, 
extracellular matrix components, and soluble proteases, can influ-
ence the exposure of different MET epitopes, thus preventing 
equal target engagement by different antibodies.
The WT52 and WT46 antibodies were selected for advanced 
preclinical testing not only because of their cooperation but also 
because each of them displayed a high antagonistic activity in con-
junction with a low agonistic activity. In fact, owing to their biva-
lent nature, antibodies directed against the MET ECD may stabi-
lize receptor homodimers, thus resulting in kinase activation (44). 
This problem can be overcome by the engineering of a monovalent 
immunoglobulin, like in the case of DN30 (29) and onartuzumab 
(30). We cannot explain why some antibodies display a more pro-
nounced agonistic activity than others; however, thanks to the 
high diversity of our antibody panel targeting a variety of different 
MET epitopes, we had the opportunity to select HGF-competing 
antibodies devoid of any relevant agonistic activity, thus making 
protein engineering dispensable.
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cells (107 cells in 1 ml of PBS; European Collection of Cell Cultures) and 
Freund’s incomplete adjuvant (Sigma-Aldrich). Animals were boosted with 
the same mix every week for 5 weeks. Generation of antibody libraries was 
performed using the proprietary SIMPLE Antibody platform (http://www.
argen-x.com/simple-antibody/). Briefly, 10 days after the last boost, 400 ml 
of blood was collected and PBLs were obtained using the Ficoll-Paque 
method (51). Total RNA was extracted as described previously (52) and 
used as template for random cDNA synthesis using the SuperScript III 
First-Strand Synthesis System kit (Life Technologies). Amplification of the 
cDNAs encoding the VH-CH1 regions of llama IgG1 and VL-CL domains 
(κ and λ) and subcloning into the phagemid vector pCB3 (Supplemental 
Figure 1) were performed as described previously (25). The E. coli strain 
TG1 (Netherlands Culture Collection of Bacteria) was transformed using 
recombinant phagemids to generate 12 different Fab-expressing phage 
libraries (one λ and one κ library per immunized llama). Diversity was in 
the range of 108–109. Fab-expressing phages were adsorbed on immobilized 
recombinant MET-Fc (R&D Systems) and eluted using trypsin as described 
previously (25). Two to four rounds of selections were performed to enrich 
for phages expressing MET-specific Fabs.
Fab screening and characterization. TG1 E. coli was infected with selected 
phages, and individual colonies were isolated. Secretion of Fabs was 
induced using IPTG (Fermentas), and the Fab-containing periplasmic frac-
tion of bacteria was collected. Binding of Fabs to human MET was deter-
mined by ELISA using MET-Fc in solid phase and periplasmic crude extract 
in solution. Binding was revealed using HRP-conjugated anti-MYC antibod-
ies (ImTec Diagnostics). Fabs that scored positive in ELISA were tested for 
their ability to compete with HGF for binding to MET. To this end, human 
MET-Fc (R&D Systems) was immobilized on ELISA plates precoated 
with anti–human Fc antibodies (Jackson ImmunoResearch Laboratories) 
and incubated with serial dilutions of Fab-containing periplasmic crude 
extract in the presence of 0.28 nM HGF (R&D Systems) biotinylated at the 
N-terminus using NHS-LC-biotin (Thermo Scientific) according to the 
manufacturer’s instruction. Binding was revealed using HRP-conjugated 
streptavidin (Sigma-Aldrich). HGF-displacing Fab clones were sent out for 
sequencing (LGC Genomics) and divided into families based on VH CDR3 
sequence length and content. VH families were given an internal number 
not based on International Immunogenetics Information System (IMGT) 
nomenclature. Binding of HGF-displacing Fabs to MET was further inves-
tigated by surface plasmon resonance using a Biacore 3000 apparatus 
(GE Healthcare). Human MET-Fc (R&D Systems) was immobilized on a 
CM-5 chip using amine coupling in sodium acetate buffer (GE Healthcare). 
The Fab-containing periplasmic extracts were loaded with a flow rate of 
30 μl/min. The Fab off-rates (koff) were measured over a 2-minute period.
Chimeric antibody production, purification, and characterization. The cDNAs 
encoding the VH and VL (κ or λ) domains of selected Fab fragments were 
engineered into 2 separate pUPE mammalian expression vectors (U-Protein 
Express) containing the cDNAs encoding CH1, CH2, and CH3 of human 
IgG1 or the human CL (κ or λ), respectively (Supplemental Figure 3B). Pro-
duction (by transient transfection of mammalian cells) and purification (by 
protein A affinity chromatography) of the resulting chimeric llama-human 
IgG1 molecules was outsourced to U-Protein Express. Binding of chimeric 
mAbs to human MET was determined by ELISA using MET ECD in solid 
phase and increasing concentrations of antibodies (0–20 nM) in solution. 
Binding was revealed using HRP-conjugated anti–human Fc antibodies 
(Jackson ImmunoResearch Laboratories). The ability of chimeric mAbs to 
compete with HGF for binding to MET was analyzed by ELISA. MET-Fc 
(R&D Systems) was immobilized on ELISA plates precoated with anti-His 
antibodies (AbD Serotec) and incubated with 0.3 nM HGF (R&D Systems) 
biotinylated as described above in the presence of increasing concentrations 
(0–100 nM) of mAbs. Binding was revealed using HRP-conjugated strep-
The preclinical results obtained with WT52 and WT46 in HGF-
dependent mouse models of cancer demonstrate that the hotspots 
identified by these 2 antibodies are valid targets for therapy. Recent 
data indicate that HGF/MET signaling plays an important role in 
glioma cell stemness, survival, and invasion (45–47). In a mouse 
model of glioblastoma multiforme, in both the s.c. and orthotopic 
settings, WT52 and WT46 inhibited tumor growth and prolonged 
mouse survival. Interestingly, in the orthotopic setting, antibody-
mediated inhibition of HGF/MET signaling resulted not only in 
reduced tumor volume (as determined by bioluminescence), but 
also in decreased brain parenchyma invasion, a feature character-
istic of glioblastoma stem cells and a negative prognostic factor in 
disease progression (48).
Neoadjuvant therapy is a common clinical practice employed 
to reduce tumor burden before surgical intervention in invasive 
mammary carcinoma. Pathological complete response at the time 
of surgery is considered a surrogate marker of clinical benefit, and 
the subsequent development of clinically detectable metastases 
negatively impacts on overall survival. In an orthotopic mouse 
model of triple-negative mammary carcinoma, in which human 
HGF is provided paracrinally by the tumor stroma, neoadjuvant 
therapy with WT52 and WT46, alone or in combination, effective-
ly reduced tumor size at the time of surgery. Most importantly, 
metastatic dissemination to the lung assessed 2 weeks later was 
dramatically decreased in the antibody arms compared with the 
control arm. These results point at a role of HGF-induced MET 
activation in sustaining breast cancer cell growth and dissemina-
tion, and warrant further exploration of HGF/MET inhibitors in 
the clinical management of triple-negative mammary carcinoma.
Colorectal carcinoma represents the second most frequent type of 
cancer worldwide, with metastatic disease being the leading cause of 
death. Metastatic colorectal tumors bearing mutations in the KRAS 
gene display the worst prognosis and are resistant to EGFR-targeted 
agents. In an orthotopic mouse model of KRAS-mutant colorectal 
cancer, in which HGF is secreted into the tumor microenvironment 
by human myofibroblasts, WT52 and WT46 — alone or in combi-
nation — significantly delayed primary tumor growth and, most 
importantly, reduced metastatic spreading to the liver, the most 
common metastatic site of colorectal cancer. This finding, in agree-
ment with previous observations (49, 50), suggests that cells bearing 
KRAS mutations, although driven by KRAS signaling, take advan-
tage of environmental HGF stimulation to invade and colonize the 
host organism. The possibility of inhibiting metastatic dissemina-
tion of KRAS-mutated cancer cells using a MET inhibitor represents 
an attractive therapeutic approach for an unmet medical need.
In conclusion, the data presented in this study, generated using 
a highly diverse panel of antagonistic antibodies, provide evidence 
that multiple regions of MET are responsible for interaction with 
its high-affinity ligand HGF, and identify several hotspots on 
the MET ECD as potential targets for therapy. Preclinical experi-
ments conducted in orthotopic mouse models of cancer indicate 
that targeting these hotspots with antagonistic antibodies is an 
effective therapeutic approach to hamper tumor progression and 
to suppress metastatic dissemination. These findings open new 
translational perspectives for HGF/MET inhibitors and provide 
novel tools for targeting this signaling pathway in human cancer.
Methods
Llama immunization, library construction, and phage selection. Six adult llamas 
were immunized with a 1:1 mixture of MKN-45 human gastric carcinoma 
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or a 2-tailed homoscedastic Student’s t test (in all other cases). A P value of 
less than 0.05 was considered statistically significant. In all figures, values 
are expressed as mean and error bars represent SEM.
Study approval. All llamas used in this study were farmed outdoors in the 
Ardèche region of France according to the French animal welfare legisla-
tion. Animal handling was limited to immunization by i.m. injection and 
peripheral blood collection. Experiments involving mice were conducted 
in the animal facility of the Candiolo Cancer Institute – FPO, IRCCS (Can-
diolo, Italy). All protocols were approved by the Fondazione Piemontese 
per la Ricerca sul Cancro ONLUS animal research ethical committee and 
by the Italian Ministry of Health according to Italian legislative guidelines 
(Decreto Legislativo n. 116 27/01/1992 and subsequent amendments).
Supplemental Methods. For all methods not listed here, please refer to the 
online Supplemental Methods section.
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tavidin (Sigma-Aldrich). Binding of chimeric mAbs to A549 human lung 
carcinoma cells was analyzed by flow cytometry using a CyAn ADP Analyzer 
(Beckman Coulter). A549 cells were incubated on ice for 30 minutes with 
increasing concentrations (0–100 nM) of mAbs. Binding was revealed using 
phycoerythrin-conjugated anti–human IgG1 antibodies (eBioscience). The 
ability of HGF to compete with mAbs for binding to A549 cells was deter-
mined by flow cytometry. A549 cells were incubated with 1 nM of each mAb 
in the presence of increasing concentrations (1–100 nM) of HGF (R&D 
Systems). Antibody binding was revealed using phycoerythrin-conjugated 
anti–human IgG1 antibodies as above. Cetuximab (Erbitux; Merck-Serono) 
was obtained from our clinical pharmacy.
Engineered MET proteins and epitope mapping. Deleted human MET pro-
teins (Supplemental Figure 4) and llama-human MET chimeras (Supple-
mental Figure 5) were generated by standard PCR and genetic engineer-
ing techniques. All deleted MET proteins conserve the leader peptide of 
human MET (GenBank X54559) at their N-terminus. Their amino acid 
(aa) sequence corresponds to aa 1–24 (leader peptide) followed by: Decoy 
MET, aa 25–932; SEMA, aa 25–515; SEMA-PSI, aa 25–562; SEMA-PSI-
IPT 1–2, aa 25–742; IPT 3–4, aa 743–932. Llama-human MET chimeras 
LS1–LS5 are composed of a llama MET portion (GenBank KF042853) at 
the N-terminus followed by a human MET portion at the C-terminus. 
Their exact amino acid sequence is described in Supplemental Figure 5. 
Human-llama MET chimeras LP6, LP7, and LI8–14 are composed of a 
human MET portion at the N-terminus followed by a llama MET por-
tion at the C-terminus. Their exact amino acid sequence is described in 
Supplemental Figure 5. Binding of chimeric mAbs to deleted MET pro-
teins and llama-human chimeras was analyzed by ELISA using engineered 
MET in solid phase and increasing concentrations (0–100 nM) of antibod-
ies in solution. Binding was revealed using HRP-conjugated anti–human 
Fc antibodies (Jackson ImmunoResearch Laboratories). Competition 
between chimeric llama-human antibodies and control antibodies (5D5, 
224G11) was determined by ELISA using 5D5 and 224G11 biotinylated 
as described above for HGF. MET-Fc (R&D Systems) was adsorbed in 
solid phase and incubated with a fixed concentration (1 nM) of either 
biotin-5D5 or biotin-224G11 in the presence of increasing concentrations 
(0–200 nM) of chimeric antibodies. Binding was revealed using HRP- 
conjugated streptavidin (Sigma-Aldrich). The same procedure was fol-
lowed to analyze competition of Fabs.
Statistics. Data related to binding, displacement, and autophosphory-
lation were analyzed and fit using Prism software (GraphPad). Biolumi-
nescence signal was analyzed using Living Image software (PerkinElmer). 
Statistical significance was determined using a log rank test (for survival) 
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